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Abstract
Background: As part of the NHLBI Family Blood Pressure Program, the Genetic Epidemiology
Network of Arteriopathy (GENOA) recruited 575 sibships (n = 1583 individuals) from Rochester,
MN who had at least two hypertensive siblings diagnosed before age 60. Linkage analysis identified
a region on chromosome 2 that was investigated using 70 single nucleotide polymorphisms (SNPs)
typed in 7 positional candidate genes, including adducin 2 (ADD2).
Method: To investigate whether blood pressure (BP) levels in these hypertensives (n = 1133)
were influenced by gene-by-drug interactions, we used cross-validation statistical methods (i.e.,
estimating a model for predicting BP levels in one subgroup and testing it in a different subgroup).
These methods greatly reduced the chance of false positive findings.
Results:  Eight SNPs in ADD2  were significantly associated with systolic BP in untreated
hypertensives (p-value < 0.05). Moreover, we also identified SNPs associated with gene-by-drug
interactions on systolic BP in drug-treated hypertensives. The TT genotype at SNP rs1541582 was
associated with an average systolic BP of 133 mmHg in the beta-blocker subgroup and 148 mmHg
in the diuretic subgroup after adjusting for overall mean differences among drug classes.
Conclusion: Our findings suggest that hypertension candidate gene variation may influence BP
responses to specific antihypertensive drug therapies and measurement of genetic variation may
assist in identifying subgroups of hypertensive patients who will benefit most from particular
antihypertensive drug therapies.
Background
Hypertension affects more than 50 million Americans and
is the most common disease for which adults seek medical
attention [1,2]. Despite the large variety and efficacy of
antihypertensive drugs, less than 50% of treated hyperten-
sives have their BP adequately controlled. It is well known
that hypertensives respond heterogeneously to antihyper-
tensive therapies, often requiring multiple medications to
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lower their BP. This heterogeneity reflects the multitude of
factors that influence interindividual variation in the
pharmacokinetic properties of drug (i.e. mechanisms of
drug absorption, distribution, metabolism, or excretion)
and pharmacodynamic properties (i.e. biochemical and
physiological mechanisms associated with the drug tar-
get). Identifying genetic variations that influence these
biochemical, physiological, and anatomical mechanisms
regulating BP response to antihypertensive therapies
could have a major public health impact on reducing the
target organ damage due to hypertension by targeting
drug interventions based on an individual's biological
profile.
As part of the National Heart Lung and Blood Institute's
Family Blood Pressure Program (FBPP), an extensive
genetic and epidemiological research effort has been
established to identify genes for hypertension and its clin-
ical complications. As part of FBPP, positional candidate
gene study of a significant linkage region on chromosome
2 (40 cM – 140 cM) implicated several hypertension sus-
ceptibility genes in this region [3]. One positional candi-
date gene implicated by the analysis was the adducin 2
gene (ADD2).  ADD2  encodes the beta subunit of the
cytoskeleton adducin heterodimeric protein and spans
108 kb including seventeen exons that are alternatively
spliced to code for at least five known protein isoforms
[4]. The adducin subunits have two structurally distinct
domains: an N-terminal globular head and a C-terminal
that contains phosphorylation sites and a MARCKS
related domain [5]. A variant of the Add2 gene was also
found to be associated with BP in rat [6]. Adducin has
been proposed to regulate renal tubular transport of Na+
reabsorption, which in turn regulates body sodium, fluid
volumes and the development of hypertension [6,7].
Genes that influence risk of developing hypertension are
prime candidates for influencing an individual's pharma-
codynamic response to blood pressure-lowering thera-
pies. Therefore, we examined whether single nucleotide
polymorphisms (SNPs) in the ADD2 gene influence BP in
hypertensives stratified by antihypertensive drug therapy
category by testing for evidence of gene-by-drug interac-
tions in a population-based sample of non-Hispanic
white hypertensives from Rochester, MN participating in
the Genetic Epidemiology Network of Arteriopathy
(GENOA) study of FBPP.
One of the basic issues in genetic association studies has
been the lack of replication of effects across studies. While
testing replication in different populations is an impor-
tant step, it does not address an emerging awareness that
there are many gene-environment and gene-gene interac-
tions underlying common traits like blood pressure [8-
10]. In fact, we would not expect the replication of these
types of effects unless the sample was from the same pop-
ulation [11]. Cross-validation is a procedure to test the
sample predictive validity on an independent dataset
which is often obtained by randomly splitting the whole
dataset into subsets [12,13]. Cross-validation has been a
critical component in gene expression microarray analysis
to assess the model predictive ability [14]. In the current
study, we have tried to derive a strategy that combines
both replication and cross-validation to identify impor-
tant genetic variations. Basically, within our sample of
hypertensives, there are 8 subgroups defined by their anti-
hypertensive therapeutic regimes. Identifying SNPs with
similar effects in multiple subgroups is one form of repli-
cation. In addition, for SNPs that influence response to
antihypertentive drugs we have the added evidence for
cross-validation methods that they predict BP levels in
independent test cases. Combined, replication and cross-
validation, provided a level of confidence that simply goes
to another epidemiological or clinical sample may not be
appropriate.
Methods
Study sample
The study was approved by the Institutional Review
Boards of all participating institutions (University of
Texas, Mayo Clinic and University of Michigan) to be
compliance with the Helsinki Declaration. Written
informed consent was obtained from each participant.
Descriptions of sample ascertainment, exclusion, and
phenotype collection for the FBPP have been previously
described [15] and are publicly available [16]. In this
study, we focused our analyses on the 1133 non-Hispanic
white, hypertensive participants from the Rochester, MN
field center which are part of the GENOA (Genetic Epide-
miology Network of Arteriopathy) component of the
FBPP. In Rochester, MN, the Mayo Clinic diagnostic index
and medical record linkage system of the Rochester Epide-
miology Project were used to identify all Olmsted County
residents less than 60 years old who had the diagnosis of
essential hypertension and received care in the county
during the previous three years [17]. Eligible probands
were contacted and asked whether they had any siblings
living in the area. If so, the siblings were contacted, and if
at least one reported the previous diagnosis of hyperten-
sion, all available members of the sibship were invited
into the study.
Study visits were conducted in the morning after an over-
night fast of at least eight hours. Using random zero
sphygmomanometers and cuffs appropriate for arm size,
three readings of blood pressure were taken in the right
arm after the participant rested in the sitting position for
at least five minutes; the last two readings were averaged
for the analyses. Participants included in the present anal-BMC Medical Genetics 2007, 8:61 http://www.biomedcentral.com/1471-2350/8/61
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yses met at least one of the following two criteria for the
diagnosis of "definite" hypertension: prior diagnosis of
hypertension by a physician and use of prescription anti-
hypertensive medication reported at the study visit; or the
second and third BP measurements obtained at the study
visit averaged ≥ 140 mm Hg for systolic pressure or ≥ 90
mm Hg for diastolic pressure.
Each prescription antihypertensive drug recorded at the
study visit was assigned a code number corresponding to
the first six digits of the Medi-Span Generic Product Iden-
tifier [18]. This number, which identifies pharmacologi-
cally equivalent drug classes, was used to categorize agents
with similar mechanisms of antihypertensive action. Par-
ticipants on monotherapies were classified as taking beta-
blockers, calcium-channel blockers, RAAS inhibitors, diu-
retics, or "other" antihypertensive drugs. Those on combi-
nation therapies were classified as taking "beta-blocker +
diuretic", "beta-blocker + other antihypertensive", "diu-
retic + other antihypertensive" or "neither beta-blocker
nor diuretic".
Genotyping
SNP genotyping for subjects from Rochester, MN was con-
ducted at the GENOA central genotyping center at the
University of Texas-Houston. SNPs were selected in posi-
tional candidate genes in the region of chromosome 2
using the public NCBI database [19] and the private Cel-
era database [20]. SNP genotyping on a total of eleven loci
in ADD2 gene (Figure 1A) was obtained using a combina-
tion of two genotyping platforms: mass spectrometer-
based detection system implemented on a Sequenom
MassARRAY system, and the fluorogenic TaqMan assay
implemented on an ABI Prism 7900 Sequence Detection
System. Primer and probe sequences are available from
the authors upon request.
Statistical analysis
The goal of this analysis was to determine if there was evi-
dence of significant SNP and drug main effects and gene-
by-drug interactions on systolic BP in hypertensives.
Because of the potentially correlated nature of the data
(given that subjects were sampled in sibships), we first
assessed the distribution of related subjects within each of
the ten treatment groups (no treatment, five monotherapy
groups and four combination therapy groups). We found
that there were few related individuals within the treat-
ment groups (Table 1). It is known that the parameter esti-
mates in regression modeling are not affected by
correlated data, however the standard errors of parameters
are underestimated [21]. We next examined differences in
the age, BMI, systolic and diastolic BP distributions across
treatment groups using an F-test. Finally, to determine if
two SNPs were likely to be representing the same variation
in the gene, we calculated   as a measure of
linkage disequilibrium (LD) between SNPs. SNPs with
high r2 values are likely to have the same genotype-pheno-
type relationship.
We next tested for SNP effects on mean levels of systolic
BP within each treatment group using linear regression
modeling, where SNP genotypes were dummy coded.
Because of the limited sample size of some of the drug cat-
egories, we used a leave-one-out cross-validation strategy
to provide more accurate estimates of the percentage of
variation in systolic BP explained by the SNPs and to
reduce reporting of false positives. The leave-one-out
cross-validation procedure leaves one person out of the
sample (designated as the test case) and estimates the
genetic model based on the N-1 remaining individuals
(designated as the training cases). The estimated model
was then applied to the test case, a predicted systolic BP
was calculated, and the residual variability between
observed and predicted values was estimated. A cross-val-
idated R2 value was then calculated by taking the total
systolic BP variation in the sample minus the total resid-
ual variation divided by the total variation. The cross-val-
idated R2 may have a negative value when the model's
prediction is poor (i.e. the predicted values deviate sub-
stantially from the observed values). We used an R2 × 100
> 0.50 cut point to identify SNPs with potential predictive
capabilities based on their performance in the test cases.
When the same SNP had a significant effect in multiple
drug classes, we considered this finding a replicated effect.
After estimating effects within each drug class, we focused
on testing for SNP-drug interactions (i.e. whether the
effects of SNPs on systolic BP differ between hypertensives
on particular classes of antihypertensive therapy). Using
analysis of covariance (ANCOVA) methods, we first tested
for overall gene-by-drug interactions using the partial F-
test, then we tested whether the SNPs effects differed
among each drug class using pairwise comparisons.
In order to minimize false inferences, we used a four-fold
cross-validation strategy in test cases to estimate the extent
to which gene-drug interactions improve prediction of
systolic BP levels beyond the influences of the main effects
of SNP variation on BP levels. For a particular pair of drugs
(e.g. beta-blocker vs. diuretic) the four-fold cross-valida-
tion strategy begins by randomly dividing the individuals
in a drug class into four equal size groups. Three of the
four subgroups from each drug class are combined into a
"training" dataset and the ANCOVA modeling strategy
outlined above was carried out in this training set to esti-
mate the model parameters that were then applied to the
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Distribution of ADD2 SNPs on Systolic Blood Pressure within treatment groups and effects of SNP-drug interactions A: The  location of the 11 SNPs on the ADD2 gene Figure 1
Distribution of ADD2 SNPs on Systolic Blood Pressure within treatment groups and effects of SNP-drug inter-
actions A: The location of the 11 SNPs on the ADD2 gene. B: Results from the analysis of each SNP on systolic blood pressure 
within each drug class. C: Results of the tests for interaction for each pair of drug classes.BMC Medical Genetics 2007, 8:61 http://www.biomedcentral.com/1471-2350/8/61
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one fourth of the data held out as the "testing" dataset.
The percent of variation in BP explained in the testing
dataset by applying the training model provides a meas-
ure of the predictive ability of the model in an independ-
ent test sample. Since there are four ways to choose three
of the four groups to create independent training-testing
sets, we have four estimates of the percent variation pre-
dicted by each SNP and its gene-drug interactions. We
took the average of the four as an overall measure of the
predictive ability of the effects of these factors.
The leave-one-out cross-validation method is an alterna-
tive to the four-fold cross-validation method when there
is not a large enough sample size to accurately model the
genetic effects in the training set (e.g. see Mushiroda et al.
2005 [22]). When we tested whether the ADD2 polymor-
phism had an effect on blood pressure levels within a
treatment class (N's ranged from 62 to 180), we thought
the sample sizes too small to carry out the four-fold cross-
validation. The general question addressed by these two
cross-validation methods is the same – that is, can an
independent test case's blood pressure level be predicted
by the training model? In the leave-one-out method, the
predictive accuracy is tallied across all independent test
cases to give a statistical average of the predictive accuracy.
Because the cross-validation method provides an alterna-
tive to the adjustment of p-values (which is often conserv-
ative and can lead to type II errors), we did not formally
adjust p-values for multiple testing. This issue is particu-
larly important in susceptibility gene research since the
small effects of relatively common alleles are likely to
have the greatest public health impact but are unlikely to
achieve p-values that withstand conservative adjustments.
By testing the predictive capability of the model on inde-
pendent test cases, cross-validation provides a more direct
assessment of whether the result is a false positive.
Results
Figure 1A presents the location of the eleven SNPs that
were genotyped in this study. One synonymous SNP is
located in exon 15, nine SNPs are located in introns and
one SNP is located in the 3' untranslated region. The aver-
age age, BMI, systolic BP and diastolic BP for individuals
in each drug class are presented in Table 1, along with a
corresponding analysis of variance to determine if the
sample means of these traits differ significantly among
drug classes. Mean age differed significantly (p < 0.001)
among the drug classes with "beta-blocker & other" hav-
ing the oldest individuals on average and RAAS inhibitors
the youngest. Overall, there was a significant effect (p <
Table 1: Distribution of antihypertensive therapies
Antihypertensive class N Number of 
sibships
Age (yrs) BMI (kg/m2) Systolic Blood Pressure 
(mmHg)
Diastolic Blood Pressure 
(mmHg)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
14 54.45 30.9
No Treatment 8 133 (11.19) (5.6) 149.45 (12.98) 86.47 (9.40)
Mono Therapies
16 55.28 30.7
Beta-Blocker 2 147 (10.38) (6.7) 134.77 (16.03) 79.00 (8.13)
56.61 29.5
CA-Blocker 62 59 (9.34) (5.3) 143.08 (15.34) 82.31 (8.99)
12 57.48 32.0
Diuretic 8 122 (9.56) (6.6) 135.27 (12.27) 79.20 (9.38)
15 54.32 31.1
RAAS Inhibitors 1 136 (9.52) (7.3) 134.13 (15.95) 80.64 (8.87)
Combination Therapies
16 59.22 32.0
Beta-Blocker + Diuretic 7 141 (9.47) (6.8) 136.81 (16.25) 77.55 (9.51)
61.67 30.7
Beta-Blocker + Other 73 68 (9.11) (5.9) 143.43 (20.40) 78.41 (9.37)
18 58.42 31.7
Diuretic + Other 0 160 (9.61) (6.4) 135.06 (15.60) 78.04 (10.01)
Neither Beta-Blocker 44 42 57.70 30.9 138.81 (18.95) 80.45 (10.55)
Nor Diuretic (9.35) (6.1)
59.61 29.4
Other Antihypertensive 18 17 (10.62) (4.8) 141.93 (23.01) 78.52 (8.81)
P-value test among drug classes* <.001 0.15 <.001 0.01
* ANOVA did not include the "no treatment" classBMC Medical Genetics 2007, 8:61 http://www.biomedcentral.com/1471-2350/8/61
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0.001) of drug class on systolic BP, with "beta-blocker +
other" associated with the highest mean levels and RAAS
inhibitors associated with the lowest mean levels of systo-
lic BP. Table 2 presents the total number of individuals
who were typed for each SNP and the frequency and per-
centage of each of the three genotypes. The numbers of
individuals in the monotherapy class of "other" antihy-
pertensive drugs (N = 18) and the combination therapy
class "neither beta-blocker nor diuretic" (N = 44) were too
small for genetic analyses and therefore were excluded
from the test of analyses.
Figure 1B presents the results from the analysis of each
SNP on systolic BP within a drug class as well as the results
from the leave-one-out cross-validation procedure. Inter-
estingly, there was replicate evidence of cross-validated
SNP effects on systolic BP in three of the eight drug cate-
gories. In the "no treatment" subgroup of hypertensives,
eight of the eleven SNPs appear to be significantly associ-
ated with systolic BP levels and six of these SNPs predicted
between 2.45% and 4.04% of the variation in systolic BP
in the test cases. Some of these same SNPs also predict lev-
els of systolic BP in the treatment groups. Among hyper-
tensives taking a diuretic, there were five SNPs that were
significantly associated with systolic BP and all of them
predicted a substantial amount of variation in systolic BP
in test cases, (cross-validated R2 ranged between 2.66%
and 6.27%). In the hypertensives taking "diuretics + other
antihypertensive", five SNPs were significantly associated
with systolic BP, but only two of them cross-validated
(cross-validated R2 was 1.88% and 1.94% for the SNPs
rs17698193 and rs3755375, respectively). The only SNP
that showed cross-validated evidence of predicting systo-
lic BP levels in all three groups was rs3755375, though in
the "no treatment" group it fell significantly below our cut
point with a cross-validated R2 × 100 = 0.28. These find-
ings alone provide preliminary evidence for gene-by-drug
interactions between ADD2 and antihypertensive agents
in determining systolic BP levels. A complete description
of the systolic BP mean levels associated with each SNP
genotype is available online as a data-supplement [see
Additional file 1].
In order to formally evaluate whether there was evidence
of SNP-by-drug interactions, we compared the effect of
each SNP on systolic BP between each drug class and used
a four-fold cross-validation strategy to reduce false posi-
tives. In Figure 1C, we summarize the results of the tests
for interaction for each pair of drug classes examined.
Some of the strongest evidence for gene-by-drug interac-
tion comes from the comparison of SNP genotype means
in the "no treatment" class relative to the antihypertensive
drug classes. This is not surprising since many SNPs have
an effect in the "no treatment" class, but do not seem to
have an influence in most of the drug classes. This is espe-
cially evident when comparing "no treatment" to the beta-
blocker treatment group. In particular, the SNP
rs2024458 genotypes are associated with a different pro-
file of mean systolic BP levels in the "beta-blocker mono-
therapy" group and the "beta-blocker + other
antihypertensive" group relative to the "no treatment"
group. Also, SNP rs3771452 appears to have different
mean systolic BP profiles in multiple drug classes, namely,
beta-blockers, calcium channel blockers, and RAAS inhib-
itors, compared to the "no treatment" group. This finding
provides initial evidence that gene effects on BP in
untreated hypertensives may be very different from gene
effects in treated hypertensives. There was also SNP-by-
drug interaction when comparing the SNP genotype
means in the "beta-blocker monotherapy" group com-
pared to the "diuretic monotherapy" group and "diuretic
+ other" antihypertensive agent.
The linkage disequilibrium pattern among variations in
the ADD2 SNPs is displayed in Figure 2. It is evident that
the relative frequency of several of the SNPs are signifi-
cantly correlated and thus the effects of each SNP alone is
likely to represent influences from multiple SNPs in this
Table 2: SNP sample size information
SNP Ntotal N11 (P11)N 12 (P12)N 22(P22)
rs2024458 983 68 (0.07) 382 (0.39) 533 (0.54)
rs3771452 936 414 (0.44) 410 (0.44) 112 (0.12)
rs1541582 945 531 (0.56) 350 (0.37) 64 (0.07)
rs2110981 1020 506 (0.50) 418 (0.41) 96 (0.09)
rs4852700 1000 611 (0.61) 353 (0.35) 36 (0.04)
rs3755375 936 514 (0.55) 364 (0.39) 58 (0.06)
rs2072246 981 549 (0.56) 374 (0.38) 58 (0.06)
rs2270042 988 544 (0.55) 384 (0.39) 60 (0.06)
rs4984 977 12 (0.01) 187 (0.19) 778 (0.80)
rs740387 977 777 (0.80) 188 (0.19) 12 (0.01)
rs17698193 997 681 (0.68) 285 (0.29) 31 (0.03)
N: number of subjects
P: genotype frequencyBMC Medical Genetics 2007, 8:61 http://www.biomedcentral.com/1471-2350/8/61
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region, either measured or unmeasured in this study.
There are three groups of SNPs that can be identified by
the linkage disequilibrium estimates (r2 > 0.95) that are
likely to be measuring the same functional variation:
group 1 (rs2024458 and rs1541582), group 2
(rs3755375, rs2072246, and rs2270042) and group 3
(rs740387 and rs4984).
Overall, there were 38 out of 308 tests (11 SNPs*28 pair-
wise comparisons) that showed significant interactions
between genetic variations in the ADD2 gene and drug
class at a α ≤ 0.05 level of significance. We expected 15 of
these significant interactions to have arisen by chance
alone (308*0.05 = 15.4). Using the cross-validation
approach, we found that 16 of the 38 significant test
results did not cross-validate which is consistent with the
expectation that 15 of the tests arise by chance alone.
Thus, the 22 cases that had cross-validated evidence of
gene-by-drug interactions are more likely to represent true
positive results. In particular, three SNPs (rs2024458,
rs3755375, and rs1541582) have consistent cross-vali-
dated differences between beta-blockers and "diuretic
monotherapy" and "diuretics + other" antihypertensive
combination regimes. These results suggest the differences
in mean BP levels depend on both a person's genotype
and upon the drug that is administered (Figure 3). In Fig-
ure 3 we illustrate this point for SNP rs1541582. We
found replicable evidence that the AT and TT genotype
classes are associated with higher systolic BP in three drug
classes – "no treatment", "diuretics" and "diuretic + oth-
ers". However, people with the AT or TT genotypes have
lower systolic BP levels in the beta-blocker group com-
pared to these other therapies.
Discussion
Hypertension is directly associated with morbidity and
mortality from stroke, myocardial infarction, and renal
failure [23-26]. Despite knowledge of the complications
of hypertension and well-recognized benefits of interven-
tions that lower BP [27,28], national surveys document
suboptimal rates of hypertension awareness, treatment,
and control [1]. One gap in our current knowledge about
predictors of BP control comes from the lack of large stud-
ies of the general population of hypertensives. While clin-
ical trials are a gold standard for directly assessing BP
responsiveness to therapies, they are typically not general-
izable to the general population of hypertensives because
of restrictive inclusion criteria, short duration of the stud-
ies, and restriction to a small set of investigative drugs
[29,30].
rs1541582 SNP by drug interactions influencing systolic  blood pressure Figure 3
rs1541582 SNP by drug interactions influencing 
systolic blood pressure. Mean levels of systolic blood 
pressure (mmHg) for the three SNP genotypes (AA, AT and 
TT) are shown for the "no treatment" (▲ ), "diuretic" (■ ), 
"diuretic + other antihypertensive" () and "beta-blocker" 
(● ) treatment groups. The error bars indicate the standard 
error of each drug-genotype class. The numbers indicate the 
number of subjects within each drug-genotype class.
Pattern of linkage disequilibrium (r2) between the 11 SNPs in  the ADD2 gene Figure 2
Pattern of linkage disequilibrium (r2) between the 11 SNPs in 
the ADD2 gene.BMC Medical Genetics 2007, 8:61 http://www.biomedcentral.com/1471-2350/8/61
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Although it has been suspected for over 50 years that
genetic variation plays an important role in determining
interindividual differences in therapeutic and toxic
responses to many medications [31], success in identify-
ing particular genes and allelic variants responsible for
such differences has been limited [32]. For antihyperten-
sive medications, only a few single gene polymorphisms
that have large effects on drug metabolizing enzymes and
thereby on BP responses have been identified. Their clini-
cal relevance is diminished, however, because most of the
agents whose metabolism is largely affected are no longer
used for treatment of hypertension. Instead, for contem-
porary antihypertensive drugs, most interindividual varia-
tion in BP response appears to arise from differences in
the targeted biochemical, physiological, and anatomical
systems regulating BP rather than in mechanisms of drug
disposition. Consequently, there is compelling rationale
to elucidate the genetic and environmental determinants
of interindividual differences in antihypertensive drug
responses – both to aid in the selection of more effective
antihypertensive drug therapy and to diagnose the patho-
genic mechanisms of hypertension in individual patients
[33].
The heterogeneous nature of hypertension is reflected in
the high degree of interindividual variability in responses
to therapy [34,35]. Biological and positional candidate
genes, like the angiotensinogen (AGT) gene, are more
likely to be associated with differences in the pathophysi-
ology of BP, differential risk of developing hypertension,
and variability in BP response to antihypertensives in the
population at large. For example, studies already indicate
the impact of AGT  and  ACE  genetic variations on BP
responsiveness to ACE  inhibitors [36,37]. In addition,
polymorphisms in the ADD1  gene, including the
Gly460Trp polymorphism, and polymorphisms in the
GNAS gene encoding the α subunits of the G proteins
have been associated with differences in response to BP
medications [38-40].
We suspected that ADD2 could be associated with differ-
ences in response to different antihypertensives because
adducins have been proposed to regulate renal tubular
transport of Na+ reabsorption and the development of
hypertension [6,7]. Mutations in the adducin α subunit in
both humans and rats have been associated with hyper-
tension [41]. Fifty percent of the BP difference between
Milan normotensive and hypertensive rat strains has been
shown to be due to point mutations in the ADD1 and
ADD2 genes [6]. Some studies have found an association
with C1797T polymorphism (rs4984) with hypertension
(particularly in the presence of ADD1 460Trp allele) and
systolic BP, depending upon the gender and genetic back-
ground of the subjects being studied [42,43].
One of the short-comings of genetic association studies is
that they have often failed to replicate and Manly [44] sug-
gests that internal validation common to good experi-
mental practices is one way to avoid the publication of
false positives. In our study, we used cross-validation
methods to significantly reduce the chance of false posi-
tives. Cross-validation methods were developed in the late
1970's as a way to incorporate a measure of predictive
accuracy (and correspondingly, a measure of prediction
error) for an estimated model based on its performance
predicting the outcome for independent test cases [45].
During the last decade, cross-validation methods have
been used widely for everything from robust variable
selection in gene expression array studies [46] to reducing
false positives in gene-gene interaction studies [47,48] to
evaluating the predictive accuracy of molecular or genetic
classifiers of disease before clinical implementation [49].
It has become a standard in the field of metabolomic [50],
proteomic [51,52], and transcriptomic [14,53] studies
because of its ease of execution and its emphasis on pre-
diction in independent test cases as a method of discrim-
inating between true associations from false associations.
We found and cross-validated a new set of ADD2 SNPs
that may also be involved in interindividual variation in
BP control in the general population of hypertensives.
One SNP (rs4984) had previously been found to be asso-
ciated with hypertension and systolic BP in predomi-
nantly normotensive general populations [42,43].
However, it was not found to be associated with BP levels
in the hypertensive population [54] which is consistent
with our findings. In this study, rs4984 was not associated
with systolic BP in the "no-treatment" group nor any of
the drug classes. And there was no evidence of any gene-
by-drug interaction for this SNP. Three SNPs (rs2024458,
rs3755375, and rs1541582) showed differences in geno-
typic effects on systolic BP in beta-blocker users versus
diuretic users. Two other SNPs (rs2072246 and
rs2270042) also predicted differences in genotypic effects
in RAAS users versus the diuretics users. Unfortunately, we
did not have the sample size to estimate haplotype effect
given the large number of variations and moderate
number of individuals in each of the drug classes. Recent
work [55] has been done in erythrocytes documenting the
role of ADD2 on intracellular sodium, potassium, and cal-
cium balance which may be a potential mechanism
through which ADD2 genotypes exert a differential effect
in diuretic users vesus other antihypertensive therapies.
For example, the thiazide diuretics inhibit Na+ and Cl-
transport in the cortical thick ascending limb and early
distal tubule. Thiazides can induce a volume contraction,
which leads to enhanced proximal tubule reabsorption of
fluid and solutes. Use of thiazides results in an increased
absorption of Ca2+ and uric acid by the proximal tubule,
ultimately leading to reduced excretion of Ca2+ and uricBMC Medical Genetics 2007, 8:61 http://www.biomedcentral.com/1471-2350/8/61
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acid. While there may be some connection in underlying
mechanisms determining blood pressure, we caution that
this is currently speculation and that more work needs to
be done to better understand the mechanisms of ADD2
genotypic variation action and interaction with antihyper-
tensive therapies.
In addition to the genetic factors, the environmental fac-
tors such as salt intake may contribute to the different
associations between populations. In a study to evaluate
the influence of ADD2 rs4984 SNP on BP in three Euro-
pean populations [42], the two populations with higher
sodium excretion showed the association between rs4984
SNP and higher BP. Other environmental factors such as
physical activity may also need to be considered to further
understand the variation in systolic BP in hypertensives.
We acknowledge that there is a fundamental limitation
inherent in our community-based study design since there
is no prospective data to document genetic influence on
blood pressure response within a person or genotype
class. Furthermore, the reason a particular patient is on a
particular drug regime is unknowable and could likely just
represent the particular prescribing preference of the phy-
sician. Because we do not expect genotype to affect pre-
scribing patterns and found similar genotype frequencies
across drug groups (analysis not shown), we considered
the gene effects we observed within a drug class a reflec-
tion of how a particular genotype reacts to a particular
drug environment. Although it is possible that these study
design issues may bias or lead to false positive findings in
our study, we have used cross-validation methods to more
accurately separate true and false positives. It seems
unlikely that the gene-drug interactions identified in our
study as being both statistically significant and accurately
predicting blood pressure in independent test cases would
result from biased false positive results. Nonetheless, care-
fully designed prospective studies, where individuals are
sampled based on genotype, are an essential next step to
externally validating our findings. We also acknowledge
that given the extensive variation in the ADD2 gene, our
investigation of 11 SNPs that were implicated in the Bar-
kley et al. [3] work represents only a limited examination
of the contribution of this gene to variation in blood pres-
sure and potential interactions with antihypertensive ther-
apies. However, our results suggest that more extensive
study of this gene is warranted to better understand the
functional genetic polymorphisms that could be operat-
ing within this gene region.
Conclusion
Our results suggest that ADD2 variation may influence BP
responses to specific antihypertensive drug therapies and
measurement of genetic variation may assist in identifying
subgroups of hypertensive patients who will benefit most
from particular antihypertensive drug therapies. Given
that BP levels are mediated by a network of multiple fac-
tors (physiological, biochemical, genetic and environ-
mental), interactions among these factors are likely to
play a major role in determining an individual's BP or
response to antihypertensive therapies. Further studies in
larger clinically representative cohorts are needed to inves-
tigate these higher order interactions. However, results of
this study indicate that it is now possible to identify
genetic variations that play a role in one key environmen-
tal interaction, namely BP response to antihypertensive
therapies.
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